PubRank

M Campieri

Author PubWeight™ 112.77‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 2000 5.34
2 Effect of an enteric-coated fish-oil preparation on relapses in Crohn's disease. N Engl J Med 1996 3.47
3 Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut 2004 3.01
4 Modulation of human dendritic cell phenotype and function by probiotic bacteria. Gut 2004 2.29
5 Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol Ther 1999 2.26
6 Treatment of ulcerative colitis with high-dose 5-aminosalicylic acid enemas. Lancet 1981 2.02
7 Enhanced mucosal interleukin-6 and -8 in Helicobacter pylori-positive dyspeptic patients. Am J Gastroenterol 1994 1.69
8 Increased expression of IP-10, IL-8, MCP-1, and MCP-3 in ulcerative colitis. Am J Pathol 1999 1.62
9 Interaction of probiotic Lactobacillus and Bifidobacterium strains with human intestinal epithelial cells: adhesion properties, competition against enteropathogens and modulation of IL-8 production. Int J Food Microbiol 2008 1.61
10 Steroid treatment in active Crohn's disease: a comparison between two regimens of different duration. Aliment Pharmacol Ther 1994 1.59
11 Reduction of oxaluria after an oral course of lactic acid bacteria at high concentration. Kidney Int 2001 1.51
12 Controlled study using wireless capsule endoscopy for the evaluation of the small intestine in chronic refractory pouchitis. Aliment Pharmacol Ther 2007 1.49
13 Beclomethasone dipropionate versus mesalazine in distal ulcerative colitis: a multicenter, randomized, double-blind study. Dig Liver Dis 2007 1.43
14 Expression of cytokines, inducible nitric oxide synthase, and matrix metalloproteinases in pouchitis: effects of probiotic treatment. Am J Gastroenterol 2001 1.43
15 Review article: the management of refractory Crohn's disease. Aliment Pharmacol Ther 2002 1.41
16 Probiotics in inflammatory bowel disease: new insight to pathogenesis or a possible therapeutic alternative? Gastroenterology 1999 1.40
17 A laboratory index for predicting relapse in asymptomatic patients with Crohn's disease. Gastroenterology 1986 1.37
18 Bacterial and fungal microbiota in relation to probiotic therapy (VSL#3) in pouchitis. Gut 2006 1.36
19 Antibiotic treatment of Crohn's disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin. Aliment Pharmacol Ther 2006 1.33
20 Rifaximin in patients with moderate or severe ulcerative colitis refractory to steroid-treatment: a double-blind, placebo-controlled trial. Dig Dis Sci 1999 1.29
21 Antibiotic combination therapy in patients with chronic, treatment-resistant pouchitis. Aliment Pharmacol Ther 1999 1.24
22 [Epidemiological study on intestinal inflammatory diseases in the Province of Bologna]. G Clin Med 1977 1.21
23 Relapsing ulcerative colitis after spinal cord stimulation: a case of intestinal neurogenic inflammation? Gastroenterology 1999 1.16
24 Rectal dialysate and fecal concentrations of neutrophil gelatinase-associated lipocalin, interleukin-8, and tumor necrosis factor-alpha in ulcerative colitis. Am J Gastroenterol 1999 1.16
25 Topical administration of 5-aminosalicylic acid enemas in patients with ulcerative colitis. Studies on rectal absorption and excretion. Gut 1985 1.15
26 Effect of probiotic strains on interleukin 8 production by HT29/19A cells. Am J Gastroenterol 2002 1.15
27 Prostaglandins, indomethacin, and ulcerative colitis. Gastroenterology 1980 1.11
28 Local injection of Infliximab for the treatment of perianal Crohn's disease. Dis Colon Rectum 2005 1.09
29 Four-week open-label trial of metronidazole and ciprofloxacin for the treatment of recurrent or refractory pouchitis. Aliment Pharmacol Ther 2002 1.07
30 Mucosal concentrations of interleukin-1 beta, interleukin-6, interleukin-8, and tumor necrosis factor-alpha in pelvic ileal pouches. Dig Dis Sci 1994 1.05
31 Anti-Saccharomyces cerevisiae antibodies (ASCA) and autoimmune liver diseases. Clin Exp Immunol 2003 1.04
32 Oral beclometasone dipropionate in the treatment of active ulcerative colitis: a double-blind placebo-controlled study. Aliment Pharmacol Ther 2002 1.04
33 Clinical trial: ulcerative colitis maintenance treatment with 5-ASA: a 1-year, randomized multicentre study comparing MMX with Asacol. Aliment Pharmacol Ther 2009 1.03
34 Rifaximin systemic absorption in patients with ulcerative colitis. Eur J Clin Pharmacol 1998 1.03
35 Rectal cell proliferation and colon cancer risk in ulcerative colitis. Cancer Res 1990 1.02
36 Changes in splanchnic hemodynamics in inflammatory bowel disease. Non-invasive assessment by Doppler ultrasound flowmetry. Scand J Gastroenterol 1992 1.01
37 Different patterns of intestinal transit time and anorectal motility in painful and painless chronic constipation. Gut 1984 0.98
38 p-ANCA and development of pouchitis in ulcerative colitis patients after proctocolectomy and ileoanal pouch anastomosis. Lancet 1994 0.98
39 Clinical course of ulcerative colitis in Italy. Digestion 1980 0.97
40 Short-term treatment with infliximab in chronic refractory pouchitis and ileitis. Aliment Pharmacol Ther 2008 0.97
41 Probiotics in infective diarrhoea and inflammatory bowel diseases. J Gastroenterol Hepatol 2000 0.97
42 Mesalazine 4 g daily given as prolonged-release granules twice daily and four times daily is at least as effective as prolonged-release tablets four times daily in patients with ulcerative colitis. Inflamm Bowel Dis 2001 0.96
43 A double-blind clinical trial to compare the effects of 4-aminosalicylic acid to 5-aminosalicylic acid in topical treatment of ulcerative colitis. Digestion 1984 0.96
44 Scavenger effect of sulfasalazine, 5-aminosalicylic acid, and olsalazine on superoxide radical generation. Dig Dis Sci 1991 0.95
45 Use of anti-tumour necrosis factor agents in inflammatory bowel disease. European guidelines for 2001-2003. Int J Colorectal Dis 2001 0.94
46 Importance of laboratory parameters in the evaluation of Crohn's disease activity. J Clin Gastroenterol 1986 0.93
47 CT-guided percutaneous pelvic abscess drainage in Crohn's disease. Tech Coloproctol 2006 0.93
48 Combined carriership of TLR9-1237C and CD14-260T alleles enhances the risk of developing chronic relapsing pouchitis. World J Gastroenterol 2005 0.91
49 Oral versus combination mesalazine therapy in active ulcerative colitis: a double-blind, double-dummy, randomized multicentre study. Aliment Pharmacol Ther 2001 0.91
50 Review--antibiotic treatment in inflammatory bowel disease: rifaximin, a new possible approach. Eur Rev Med Pharmacol Sci 2000 0.91
51 Specificity of leucocyte migration inhibition test in coeliac disease. A reassessment using different gluten subfractions. Clin Exp Immunol 1985 0.90
52 New insights into the brain involvement in patients with Crohn's disease: a voxel-based morphometry study. Neurogastroenterol Motil 2012 0.90
53 Placebo-controlled trial of oral 5-ASA in relapse prevention of Crohn's disease. Dig Dis Sci 1992 0.90
54 Salicylate other than 5-aminosalicylic acid ineffective in ulcerative colitis. Lancet 1978 0.89
55 Potential role of the cannabinoid receptor CB in the pathogenesis of erosive and non-erosive gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2010 0.89
56 Oral budesonide in the treatment of chronic refractory pouchitis. Aliment Pharmacol Ther 2007 0.88
57 Assessment of nutritional status in Crohn's disease in remission or low activity. Hepatogastroenterology 1984 0.87
58 Comparison of mesalazine suppositories in proctitis and distal proctosigmoiditis. Aliment Pharmacol Ther 1997 0.87
59 Interleukin 1 in ulcerative colitis. Gut 1991 0.86
60 Review article: treatment of mild to moderate ulcerative colitis and pouchitis. Aliment Pharmacol Ther 2002 0.86
61 Clinical features in familial cases of Crohn's disease and ulcerative colitis in Italy: a GISC study. Italian Study Group for the Disease of Colon and Rectum. Am J Gastroenterol 2001 0.86
62 Long-term efficacy of bismuth carbomer enemas in patients with treatment-resistant chronic pouchitis. Aliment Pharmacol Ther 1997 0.85
63 Intracolonic release of nitric oxide during trinitrobenzene sulfonic acid rat colitis. Dig Dis Sci 1997 0.85
64 A possible mechanism of action of sulfasalazine and 5-aminosalicylic acid in inflammatory bowel diseases: interaction with oxygen free radicals. Gastroenterology 1985 0.85
65 Respiratory burst of circulating polymorphonuclear leukocytes and plasma elastase levels in patients with inflammatory bowel disease in remission. Dig Dis Sci 1994 0.85
66 Comparison of oral with rectal mesalazine in the treatment of ulcerative proctitis. Dis Colon Rectum 1998 0.85
67 Interleukin 1 beta (IL-1 beta) release from fresh and cultured colonic mucosa in patients with ulcerative colitis (UC). Agents Actions 1992 0.85
68 The effect of transient intestinal ischemia on inflammatory parameters. Int J Colorectal Dis 2002 0.84
69 Retrograde spread of 5-aminosalicylic acid enemas in patients with active ulcerative colitis. Dis Colon Rectum 1986 0.84
70 Retrograde colonic spread of a new mesalazine rectal enema in patients with distal ulcerative colitis. Aliment Pharmacol Ther 1997 0.84
71 Management of severe ulcerative colitis with the help of high resolution ultrasonography. Am J Gastroenterol 1996 0.83
72 Oral budesonide as maintenance therapy in Crohn's disease--results of a 12-month study. Global Budesonide Study Group. Aliment Pharmacol Ther 1998 0.83
73 A new mesalazine gel enema in the treatment of left-sided ulcerative colitis: a randomized controlled multicentre trial. Aliment Pharmacol Ther 1999 0.83
74 Activation of signal-transducer and activator of transcription 1 (STAT1) in pouchitis. Clin Exp Immunol 2001 0.83
75 Recognition of bactericidal/permeability-increasing protein by perinuclear anti-neutrophil cytoplasmic antibody-positive sera from ulcerative colitis patients: prevalence and clinical significance. Scand J Gastroenterol 1998 0.83
76 Probiotics and antibiotics in inflammatory bowel disease. Curr Opin Gastroenterol 2001 0.82
77 Risk of permanent stoma in extensive Crohn's colitis: the impact of biological drugs. Colorectal Dis 2013 0.82
78 Probiotics--role in inflammatory bowel disease. Dig Liver Dis 2002 0.81
79 Lack of effect of antineutrophil cytoplasmic antibodies associated with ulcerative colitis on superoxide anion production from neutrophils. Gut 1997 0.81
80 Maintenance treatment of ulcerative proctitis with mesalazine suppositories: a double-blind placebo-controlled trial. The Italian IBD Study Group. Am J Gastroenterol 1998 0.81
81 5-aminosalicylic acid as rectal enema in ulcerative colitis patients unable to take sulphasalazine. Lancet 1984 0.79
82 Review article: medical treatment of severe ulcerative colitis. Aliment Pharmacol Ther 2003 0.79
83 The possible utility of steroids in the prevention of relapses of Crohn's disease in remission. A preliminary study. J Clin Gastroenterol 1988 0.79
84 Reduction by cimetropium bromide of the colonic motor response to eating in patients with the irritable bowel syndrome. Eur J Clin Pharmacol 1988 0.79
85 Anorectal manometry in the diagnosis of Hirschsprung's disease--comparison with clinical and radiological criteria. Am J Gastroenterol 1984 0.79
86 Dietary allergy evaluated by PRIST and RAST in inflammatory bowel disease. Hepatogastroenterology 1986 0.78
87 Intestinal microflora and oral bacteriotherapy in irritable bowel syndrome. Dig Liver Dis 2002 0.78
88 Selective cyclooxygenase-2 silencing mediated by engineered E. coli and RNA interference induces anti-tumour effects in human colon cancer cells. Br J Cancer 2010 0.78
89 Review article: monitoring activity in ulcerative colitis. Aliment Pharmacol Ther 2002 0.78
90 Effects of new fish oil derivative on fatty acid phospholipid-membrane pattern in a group of Crohn's disease patients. Dig Dis Sci 1994 0.78
91 Influence of steroid treatment's duration in patients with active Crohn's disease. Agents Actions 1992 0.77
92 Scavenger effect of sulphasalazine (SASP), 5-aminosalicylic acid (5-ASA), and olsalazine (OAZ) Gut 1990 0.77
93 Bronchopulmonary involvement in ulcerative colitis. J Clin Gastroenterol 1990 0.77
94 Distinct proteomic profiles characterise non-erosive from erosive reflux disease. Aliment Pharmacol Ther 2011 0.76
95 Review article: problematic proctitis and distal colitis. Aliment Pharmacol Ther 2004 0.76
96 Randomized controlled trials in pouchitis. Rev Recent Clin Trials 2012 0.76
97 Oral beclomethasone dipropionate in patients with mild to moderate ulcerative colitis: a dose-finding study. Adv Ther 2002 0.76
98 Probiotics and barrier function in colitis. Gut 2005 0.75
99 Analysis of biological variables in Crohn's disease. Gut 1996 0.75
100 Macrophage subpopulations in pouchitis. Gut 1992 0.75
101 Polyunsaturated fatty acid pattern and fish oil treatment in inflammatory bowel disease. Gut 1993 0.75
102 MCP-3 in inflammatory bowel disease. Gut 2000 0.75
103 Ultrasonographic findings in Crohn's disease. Gut 2000 0.75
104 Pentasa in maintenance treatment of ulcerative colitis. Gastroenterology 1990 0.75
105 Effect of domperidone and dopamine on colonic motor activity in patients with the irritable bowel syndrome. Eur J Clin Pharmacol 1985 0.75
106 [Immediate and long-term results in ileoanastomosis with reservoir in 335 consecutive cases]. Chir Ital 2000 0.75
107 Systemic availability of 5-aminosalicylic acid: comparison of delayed release and an azo-bond preparation. Aliment Pharmacol Ther 1996 0.75
108 Bioavailability of single and multiple doses of a new oral formulation of 5-ASA in patients with inflammatory bowel disease and healthy volunteers. Aliment Pharmacol Ther 1994 0.75
109 5-aminosalicylic acid for the treatment of inflammatory bowel diseases. Gastroenterology 1985 0.75
110 Inhibition of postprandial colonic motility by sulpiride in patients with irritable colon. Eur J Clin Pharmacol 1983 0.75
111 [Value of rectal biopsy in inflammatory intestinal diseases]. G Clin Med 1979 0.75
112 Short report: zinc sulphate supplementation corrects abnormal erythrocyte membrane long-chain fatty acid composition in patients with Crohn's disease. Aliment Pharmacol Ther 1994 0.75
113 Sulphasalazine and new related compounds. Trop Gastroenterol 1989 0.75
114 Levels of zinc and thymulin in plasma from patients with Crohn's disease. J Clin Lab Immunol 1990 0.75
115 Clinical course of Crohn's disease in Italy. Dis Colon Rectum 1987 0.75
116 [Effects of Tettuccio water from the Montecatini spa on chronic constipation: clinical evaluation and study of intestinal motor activity]. Clin Ter 1984 0.75
117 5-Aminosalicylic acid in patients with ulcerative colitis in remission: plasma levels after administration of a new rectal enema. Methods Find Exp Clin Pharmacol 1988 0.75
118 Skin tests for coeliac disease. Lancet 1979 0.75
119 [Data concerning motility of the sigmoid colon in patients with chronic ulcerative colitis]. Minerva Dietol Gastroenterol 1979 0.75
120 [Gastric tolerance of diphenpyramide after long-term treatment. Evaluation of the electric potential difference in the stomach]. Clin Ter 1982 0.75
121 Antispasmodic activity of rociverine. Manometric findings and controlled clinical trial. Panminerva Med 1980 0.75
122 Recommendations for New Trials of Currently Available Therapy by the IOIBD Task Force on Clinical Trials*. Inflamm Bowel Dis 1995 0.75
123 Which therapies are advisable in pouchitis? Inflamm Bowel Dis 2008 0.75
124 Calorie supplementation and Crohn's disease. Lancet 1983 0.75
125 [Clinical and prognostic aspects of chronic ulcerative colitis]. Recenti Prog Med 1979 0.75
126 [Use of the cutaneous test with the Oxford fraction B2 in diagnosis of celiac disease. Results of the test in a group of 10 subjects of pediatric age and their relatives]. Recenti Prog Med 1979 0.75
127 Medical treatment and management of severe ulcerative colitis. Dig Liver Dis 2008 0.75
128 [Abdominal scintigraphy with leukocytes marked with indium-111 in Crohn disease: clinical importance and prognostic usefulness]. Ann Ital Med Int 1991 0.75
129 Review article: aminosalicylates for distal colitis. Aliment Pharmacol Ther 2006 0.75
130 Serum zinc concentrations in Crohn's disease. Dig Dis Sci 1982 0.75